Document is current
Any future updates will be listed below
-
Authors
Marcucci, Maura https://orcid.org/0000-0002-8468-7991
Painter, Thomas W.
Conen, David
Leslie, Kate
Lomivorotov, Vladimir V.
Sessler, Daniel
Chan, Matthew T. V.
Borges, Flavia K.
Martínez Zapata, Maria J.
Wang, C. Y.
Xavier, Denis
Ofori, Sandra N.
Landoni, Giovanni
Efremov, Sergey
Kleinlugtenbelt, Ydo V.
Szczeklik, Wojciech
Schmartz, Denis
Garg, Amit X.
Short, Timothy G.
Wittmann, Maria
Meyhoff, Christian S.
Amir, Mohammed
Torres, David
Patel, Ameen
Duceppe, Emmanuelle
Ruetzler, Kurtz
Parlow, Joel L.
Tandon, Vikas
Wang, Michael K.
Fleischmann, Edith
Polanczyk, Carisi A.
Jayaram, Raja
Astrakov, Sergey V.
Rao, Mangala
VanHelder, Tomas
Wu, William K. K.
Cheong, Chao Chia
Ayad, Sabry
Abubakirov, Marat
Kirov, Mikhail
Bhatt, Keyur
de Nadal, Miriam
Likhvantsev, Valery
Iglesisas, Pilar Paniagua
Aguado, Hector J.
McGillion, Michael
Lamy, Andre
Whitlock, Richard P.
Roshanov, Pavel
Stillo, David
Copland, Ingrid
Vincent, Jessica
Balasubramanian, Kumar
Bangdiwala, Shrikant I.
Biccard, Bruce
Kurz, Andrea
Srinathan, Sadeesh
Petit, Shirley
Eikelboom, John
Richards, Toby
Gross, Peter L.
Alfonsi, Pascal
Guyatt, Gordon
Belley-Cote, Emily
Spence, Jessica
McIntyre, William
Yusuf, Salim
Devereaux, P. J.
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research (FDN-143302)
Research Grant Council, Hong Kong SAR (14104419)
National Health and Medical Research Council, Australia (1162362)
- License Information
-
More Information
Article History
Received: 24 September 2021
Accepted: 29 December 2021
First Online: 31 January 2022
Declarations
:
: This trial is conducted in compliance with the protocol, the Declaration of Helsinki, the International Consensus on Harmonization - Good Clinical Practice (ICH-GCP), and all applicable laws and regulations of the countries in which the study is performed. Before sites start recruiting patients, the local investigators must have written and dated approval/favorable opinion from the Institutional Review Board/Independent Ethics Committee (IRB/IEC) for the protocol, consent form (Additional File ), subject recruitment materials/process and, where applicable, approval by the participating countries Competent Authority (CA) in accordance with local laws and regulations. Amendments to the protocol also require IRB/IEC and/or CA approval, where applicable. All data are stored on a central encrypted, high-security computer system and kept strictly confidential. There is no anticipated harm and compensation for participants who suffer harm from trial participation. There is no plan for provision of any post-trial care. This trial does not involve collecting biological specimens for storage.
: Not applicable.
: ED acknowledges Investigator initiated research grants from Roche Diagnostics, Abbott Laboratories and Boehringer Ingelheim; lecture fee and honoraria for participation in advisory board meeting by Roche Diagnostics; support by a Fonds de Recherche en Sante du Quebec salary award. MJM-Z is supported by a Miguel Servet II research contract from the ISCIII (CP1120/00023), Spain. CSM: has co-founded a start-up company, WARD247 ApS, with the aim of pursuing the regulatory and commercial activities of the WARD-project, an Innovation Fund Denmark funded research project on wireless vital signs. CSM also reports direct and indirect research funding to his department from Ferring Pharmaceuticals, Merck, Sharp & Dohme Corp. and Boehringer Ingelheim outside the submitted work as well as lecture fees from Radiometer. DT received speaker honorarium from 3 M and Pfizer. EB-C received grants from Bayer, Roche, and BMS-Pfizer. AP acknowledges to have provided expertise and have been speaker for Laboratory Edwards, 3 M, and MSD laboratories; to have been speaker for Pfizer. AXG is supported by the Dr. Adam Linton Chair in Kidney Health Analytics. PLG has received speaker fees from Bayer, Bristol-Myers-Squibb, Pfizer, Leo Pharma and Valeo. TR reports grants from UK, NIHR HTA; grants from Australian, NHMRC; grants, personal fees and non-financial support from Pharmocosmos; grants, personal fees and non-financial support from Vifor Pharma; grants from UK, NIHR EME; grants from Australian MRFF; grants from Western Australia FHRF; grants and personal fees from Pfizer Australia; personal fees from BioAge Labs, outside the submitted work; and TR is a regular speaker at national and international conferences on anemia, blood transfusion, wound healing and vascular diseases for which he has received expenses for travel, accommodation and sundries. TR has worked with several agencies promoting meetings or healthcare. TR is a director of The Iron Clinic Ltd and director of Veincare London Ltd & Veincare WA also TR is the Vascular lead for 18-week wait Ltd. All the other co-authors report no conflict of interest.
